ENDPOINTS NEWS3h
Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts
Amgen's obesity drug AMG-513 on clinical hold; company reaffirms obesity market ambitions while advancing MariTide program ...
ENDPOINTS NEWS4h
No­vo Nordisk sees growth slow­ing this year, plans Ca­griSe­ma fil­ing for 2026
Novo Nordisk reports 26% sales growth in 2024, but projects lower 2025 growth of 16-24%. Full-year Wegovy sales up 86%, ...
ENDPOINTS NEWS3h
GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas
GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, ...
ENDPOINTS NEWS18h
J&J asks court for quick de­ci­sion in 340B re­bate mod­el fight
Johnson & Johnson has asked a federal district court to expedite its decision in a case over the company’s proposed 340B ...
ENDPOINTS NEWS22h
We’re about to find out which RFK Jr. will show up at HHS
Robert F. Kennedy Jr. advances toward Senate confirmation despite vaccine controversy, as key skeptic Sen. Bill Cassidy backs ...
ENDPOINTS NEWS22h
Il­lu­mi­na added to Chi­na's black­list fol­low­ing Biose­cure Act, tar­iffs
China tensions, following US restrictions on Chinese rivals BGI and MGI. Illumina says China accounts for 7% of Q3 revenue.
ENDPOINTS NEWS23h
FDA ap­proves Su­per­nus’ Parkin­son’s drug-de­vice af­ter two re­jec­tions
At long last, the FDA approved Supernus Pharmaceuticals’ Parkinson’s disease treatment, which will be marketed as Onapgo.